An examination of the efficacy and background of the Covid-19 vaccine: comparative analysis
Significance and Aim: The aim of this review is to instigate the existing literature on the efficacy levels of the administered Covid-19 pandemic vaccines. The review examines how the efficacy levels compare or contrast among the leading vaccines globally. The proposed value of the review is to in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Medwin
2021
|
| _version_ | 1825937626935328768 |
|---|---|
| author | Mahmoud, Al-Masaeed M., Alghawanmeh A., Al-Singlawi R., Alsababha M., Alqudah A., Alomari M., Alshawawreh Rasdi, Irniza |
| author_facet | Mahmoud, Al-Masaeed M., Alghawanmeh A., Al-Singlawi R., Alsababha M., Alqudah A., Alomari M., Alshawawreh Rasdi, Irniza |
| author_sort | Mahmoud, Al-Masaeed |
| collection | UPM |
| description | Significance and Aim: The aim of this review is to instigate the existing literature on the efficacy levels of the administered
Covid-19 pandemic vaccines. The review examines how the efficacy levels compare or contrast among the leading vaccines
globally. The proposed value of the review is to indicate if the inoculation of the population has a significant value and impact
on reducing exposure and risk of Covid-19 infection and severity of the disease. Methods: The review was developed as an ILR analysis. The search was made from 5 different databases. The findings were
Scopus (103), Medline (78), Google Scholar (320), CINAHL (167), and WHO (201). By applying the review inclusion and exclusion criteria, the review settled on 21 articles included in the analysis. The findings were analysed thematically. Results and findings: The findings indicate that the vaccines analysed, the (i) Pfizer, (ii) Astra Zeneca, (iii) Johnson &, (iv) Moderna, can be categorised into two main levels, namely the mRNA vaccines and the carrier/ virus vector vaccines. The findings indicate that all the vaccines have a high efficacy index above the WHO threshold of 50% efficacy minimum. Pfizer has the highest efficacy based on the RCTs done at the manufacturing stage. Conclusion: In summary, the findings indicate the validity and value of vaccines in reducing the healthcare industry burden. The high efficacy levels on reducing the severity and hospitalisation needs allow for a reduced disease burden globally. Sensitisation is required for the global population base. Equally, more RCTs are required to test the efficacy of the existing
vaccines against the emerging variants, such as the highly virulent delta variant. |
| first_indexed | 2024-03-06T11:02:23Z |
| format | Article |
| id | upm.eprints-95848 |
| institution | Universiti Putra Malaysia |
| last_indexed | 2024-03-06T11:02:23Z |
| publishDate | 2021 |
| publisher | Medwin |
| record_format | dspace |
| spelling | upm.eprints-958482023-03-29T03:36:08Z http://psasir.upm.edu.my/id/eprint/95848/ An examination of the efficacy and background of the Covid-19 vaccine: comparative analysis Mahmoud, Al-Masaeed M., Alghawanmeh A., Al-Singlawi R., Alsababha M., Alqudah A., Alomari M., Alshawawreh Rasdi, Irniza Significance and Aim: The aim of this review is to instigate the existing literature on the efficacy levels of the administered Covid-19 pandemic vaccines. The review examines how the efficacy levels compare or contrast among the leading vaccines globally. The proposed value of the review is to indicate if the inoculation of the population has a significant value and impact on reducing exposure and risk of Covid-19 infection and severity of the disease. Methods: The review was developed as an ILR analysis. The search was made from 5 different databases. The findings were Scopus (103), Medline (78), Google Scholar (320), CINAHL (167), and WHO (201). By applying the review inclusion and exclusion criteria, the review settled on 21 articles included in the analysis. The findings were analysed thematically. Results and findings: The findings indicate that the vaccines analysed, the (i) Pfizer, (ii) Astra Zeneca, (iii) Johnson &, (iv) Moderna, can be categorised into two main levels, namely the mRNA vaccines and the carrier/ virus vector vaccines. The findings indicate that all the vaccines have a high efficacy index above the WHO threshold of 50% efficacy minimum. Pfizer has the highest efficacy based on the RCTs done at the manufacturing stage. Conclusion: In summary, the findings indicate the validity and value of vaccines in reducing the healthcare industry burden. The high efficacy levels on reducing the severity and hospitalisation needs allow for a reduced disease burden globally. Sensitisation is required for the global population base. Equally, more RCTs are required to test the efficacy of the existing vaccines against the emerging variants, such as the highly virulent delta variant. Medwin 2021 Article PeerReviewed Mahmoud, Al-Masaeed and M., Alghawanmeh and A., Al-Singlawi and R., Alsababha and M., Alqudah and A., Alomari and M., Alshawawreh and Rasdi, Irniza (2021) An examination of the efficacy and background of the Covid-19 vaccine: comparative analysis. Journal of Quality in Healthcare and Economics, 4 (5). pp. 1-6. ISSN 2642-6250 https://medwinpublishers.com/JQHE/ 10.23880/jqhe-16000239 |
| spellingShingle | Mahmoud, Al-Masaeed M., Alghawanmeh A., Al-Singlawi R., Alsababha M., Alqudah A., Alomari M., Alshawawreh Rasdi, Irniza An examination of the efficacy and background of the Covid-19 vaccine: comparative analysis |
| title | An examination of the efficacy and background of the Covid-19
vaccine: comparative analysis |
| title_full | An examination of the efficacy and background of the Covid-19
vaccine: comparative analysis |
| title_fullStr | An examination of the efficacy and background of the Covid-19
vaccine: comparative analysis |
| title_full_unstemmed | An examination of the efficacy and background of the Covid-19
vaccine: comparative analysis |
| title_short | An examination of the efficacy and background of the Covid-19
vaccine: comparative analysis |
| title_sort | examination of the efficacy and background of the covid 19 vaccine comparative analysis |
| work_keys_str_mv | AT mahmoudalmasaeed anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malghawanmeh anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT aalsinglawi anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT ralsababha anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malqudah anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT aalomari anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malshawawreh anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT rasdiirniza anexaminationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT mahmoudalmasaeed examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malghawanmeh examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT aalsinglawi examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT ralsababha examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malqudah examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT aalomari examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT malshawawreh examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis AT rasdiirniza examinationoftheefficacyandbackgroundofthecovid19vaccinecomparativeanalysis |